

AMERICAN ASSOCIATION OF  
NEUROLOGICAL SURGEONS

KATHLEEN T. CRAIG, *Executive Director*  
5550 Meadowbrook Drive  
Rolling Meadows, IL 60008  
Phone: 888-566-AANS  
Fax: 847-378-0600  
info@aans.org



CONGRESS OF  
NEUROLOGICAL SURGEONS

REGINA SHUPAK, *CEO*  
10 North Martingale Road, Suite 190  
Schaumburg, IL 60173  
Phone: 877-517-1CNS  
FAX: 847-240-0804  
info@1CNS.org

*President*  
FREDERICK A. BOOP, MD  
Memphis, Tennessee

*President*  
RUSSELL R. LONSER, MD  
Columbus, Ohio

June 6, 2016

Carlos L. Pena, PhD, Director  
Division of Neurological and Physical Medicine Devices  
FDA, Center for Devices and Radiological Health  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

**Subject: Clinical Considerations for Investigational Device Exceptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes; Draft Guidance Document for Industry and FDA Staff**

Dear Dr. Pena:

On behalf of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS), we would like to thank you and your staff for developing the above referenced Guidance Document for Investigational Device Exemptions (IDEs) for devices that target the cause or progression of disorders such as Alzheimer's, Parkinson's or Primary Dystonia.

We agree with the agency that neurological devices such as neurostimulators designed to slow disease progression and improve clinical outcomes represent a revolutionary option for patients, giving hope where no successful treatment was previously available. These devices address a significant unmet need for patients with devastating conditions. We commend FDA staff for issuing the proposed rule to help manufacturers work with the agency as efficiently as possible to make safe and effective medical devices available. We look forward to seeing the final guidance document.

Thank you for your time and attention. We appreciate the dedication and expertise of the FDA staff and are eager to continue to work together on behalf of our patients.

Sincerely,



Frederick A. Boop, MD, President  
American Association of Neurological Surgeons



Russell R. Lonser, President  
Congress of Neurological Surgeons

**Staff Contact:**

Catherine Jeakle Hill  
Senior Manager, Regulatory Affairs  
American Association of Neurological Surgeons/  
Congress of Neurological Surgeons  
725 15th Street, NW, Suite 500  
Washington, DC 20005  
Phone: 202-446-2026  
Fax: 202-628-5264  
E-mail: [chill@neurosurgery.org](mailto:chill@neurosurgery.org)